ASKA Pharmaceutical Holdings said on June 20 that its subsidiary ASKA Pharmaceutical has granted rights to exclusively develop and commercialize the oral contraceptive drospirenone in South Korea to Hyundai Pharm. Under the deal, Hyundai Pharm obtained the development and commercialization…
To read the full story
Related Article
- Insud’s Oral Contraceptive Filed in South Korea: ASKA
April 10, 2023
- ASKA Grabs Japan, South Korea Rights to Insud’s Oral Contraceptive
January 9, 2020
BUSINESS
- Shionogi, Susmed End Sales Partnership for Insomnia App
August 27, 2026
- Nxera to Earn US$10 Million Milestone as Alzheimer’s Candidate Moves to PII
August 27, 2026
- Takeda’s XFG-Targeted COVID Jab Approved in Japan
August 27, 2026
- Meiji Wins Japan Approval for NB.1.8.1-Adapted COVID Vaccine
August 27, 2026
- Japan Pharma Market Seen Topping 11 Trillion Yen by 2035: Fuji Keizai
August 26, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





